Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053)
Sarepta Announces Agreement with Nationwide Children’s Hospital for Rights to its Gene Therapy Program
Pharmaceutical Investing Sarepta Therapeutics Announces Fourth Quarter 2017 and Full-Year 2017 Financial Results
Cartier Resources Closes Offering with Paradigm Capital and Concurrent Offering for Aggregate Gross Proceeds of $11,398,596
